Polynitroxylated pegylated haemoglobin - SynZyme Technologies

Drug Profile

Polynitroxylated pegylated haemoglobin - SynZyme Technologies

Alternative Names: HemoZyme; nanoRBC; PEG-haemoglobin - SynZyme; SanFlow

Latest Information Update: 11 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SynZyme Technologies
  • Class Haemoglobins; Polyethylene glycols
  • Mechanism of Action Nitric oxide donors; Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain injuries

Most Recent Events

  • 02 Aug 2016 Polynitroxylated pegylated haemoglobin - SynZyme is available for licensing -http://www.synzyme.com/gallery.html
  • 02 Aug 2016 Preclinical trials in Brain injuries in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top